JR-131 vs Loncipoetin alfa (NuPIAO)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
JR-131
Marketed by Kissei Pharmaceutical and partners
NCT02912494 · Phase 3 · completed
The study was double-blind and used an active darbepoetin alfa comparator, but the registry does not state whether participants were randomized or report the sample size. Its primary endpoint was change in hemoglobin, a surrogate measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Change from baseline in Hemoglobin level (24 weeks): Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL (met)
Result source: NCT02912494
Loncipoetin alfa (NuPIAO)
Marketed by Shenyang Sunshine Pharmaceutical
NCT05211167 · Phase 3 · status unknown
This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Reported efficacy
hemoglobin concentration (25th-32nd week): Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given. (met)
Result source: NCT05211167
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | JR-131 | Loncipoetin alfa (NuPIAO) |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT02912494 | —Not reported |
| UACR, % change | —Not posted · NCT02912494 | —Not reported |
| eGFR slope | —Not posted · NCT02912494 | —Not reported |
| Haemoglobin, change | —Not posted · NCT02912494 | —Not reported |
Kidney composite outcome
- JR-131
- —Not posted · NCT02912494
- Loncipoetin alfa (NuPIAO)
- —Not reported
UACR, % change
- JR-131
- —Not posted · NCT02912494
- Loncipoetin alfa (NuPIAO)
- —Not reported
eGFR slope
- JR-131
- —Not posted · NCT02912494
- Loncipoetin alfa (NuPIAO)
- —Not reported
Haemoglobin, change
- JR-131
- —Not posted · NCT02912494
- Loncipoetin alfa (NuPIAO)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JR-131's landscape · Loncipoetin alfa (NuPIAO)'s landscape